Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Vividion Therapeutics, Inc.
QuantumLeap Healthcare Collaborative
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Eisai Inc.
Amgen
Hoffmann-La Roche
Hoffmann-La Roche
AbbVie
Università Vita-Salute San Raffaele
UNICANCER
University of Kentucky
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
National University Hospital, Singapore
Nurix Therapeutics, Inc.
Tesaro, Inc.
AbbVie
Sun Yat-sen University
DEKA Biosciences
Mario Negri Institute for Pharmacological Research
Shandong Cancer Hospital and Institute